CDK4 and prostate carcinoma: Moreover, TRIB3, which is highly expressed in prostate cancer, can be targeted by Palbociclib, a CDK4/6 inhibitor approved for the treatment of breast cancer, augmenting the response of prostate cancer cells to ferroptosis inducers [76].